PDCD1 and non-small cell lung carcinoma: Lu et al. in their 2020 Nature Medicine paper explored the safety and feasibility of PD-1 targeting CRISPR edited T-cells in therapeutic management of advanced non-small-cell lung cancer (NSCLC) patients.